Series: Cardiovascular outcome trials for diabetes drugs Degludec and DEVOTE
نویسندگان
چکیده
منابع مشابه
Updates on cardiovascular outcome trials in diabetes
In 2008 the Food and Drug Administration introduced a guidance for industry that requires the investigation of cardiovascular outcomes of glucose-lowering medications. Since then, an increasing number of cardiovascular outcome trials have been completed in diabetes patients with high cardiovascular risk for members of the SGLT-2 and DPP4 inhibitors and GLP-1 receptor agonist classes. The trials...
متن کاملResults from Cardiovascular Outcome Trials in Diabetes.
Los pacientes con diabetes mellitus tipo 2 (DM2) tienen un riesgo de enfermedad cardiovascular (ECV) elevado tanto por la hiperglucemia como por otros factores de riesgo vascular asociados y, además, un peor pronóstico ante los eventos cardiovasculares. La diabetes acentúa la gravedad de todas las fases de la aterosclerosis, su desarrollo y sus complicaciones. En los pacientes con diabetes exis...
متن کاملRecent cardiovascular outcome trials of antidiabetic drugs: A comparative analysis
Since the rosiglitazone controversy, the US Food Drug Administration (USFDA) in the year 2008, mandated that all new antidiabetic agents must undergo an adequately powered, glycemic‐equipoised, cardiovascular (CV) outcome trial (CVOT) in high‐risk Type 2 diabetic patients, during postmarketing phase to demonstrate its safety by showing noninferiority against placebo. While noninferiority was de...
متن کاملDiabetes medications and cardiovascular outcome trials: Lessons learned.
The US Food and Drug Administration's current standards require that new diabetes medications demonstrate cardiovascular safety in large, long-term trials. New drugs that have been assessed in such trials are changing the management of type 2 diabetes.
متن کاملCurrent perspectives on cardiovascular outcome trials in diabetes
Cardiovascular disease (CVD) is one of the most common diabetes-associated complications, as well as a leading cause for death in type 2 diabetes patients (T2D). Despite the well-known correlation between the two, up until the 2008 FDA industry guidance for licensing of new anti-hyperglycemic drugs, which required an investigation of cardiovascular outcomes (CVO) of glucose-lowering agents, onl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Diabetes
سال: 2021
ISSN: 2397-6241,2397-6233
DOI: 10.15277/bjd.2021.302